FY2025 EPS Estimate for Anixa Biosciences Boosted by Analyst

Key Points

• HC Wainwright has increased its FY2025 EPS estimates for Anixa Biosciences to ($0.35) per share, slightly up from a previous estimate of ($0.38), while maintaining a "Buy" rating with a price target of $7.00.
• The consensus estimate for Anixa Biosciences' full-year earnings stands at ($0.41) per share, indicating a potential upside compared to the increased estimates from analysts.
• Anixa's stock has a current average rating of "Buy" from multiple analysts, with a consensus price target of $9.00, reflecting positive sentiment towards the company's performance.

Anixa Biosciences Inc (NASDAQ:ANIX - Free Report) - Equities research analysts at HC Wainwright raised their FY2025 earnings estimates for shares of Anixa Biosciences in a report released on Thursday, September 11th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.35) per share for the year, up from their previous forecast of ($0.38). HC Wainwright has a "Buy" rating and a $7.00 price objective on the stock. The consensus estimate for Anixa Biosciences' current full-year earnings is ($0.41) per share. HC Wainwright also issued estimates for Anixa Biosciences' Q4 2025 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.38) EPS.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its earnings results on Wednesday, September 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03.

ANIX has been the subject of several other reports. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, September 9th. Wall Street Zen upgraded shares of Anixa Biosciences from a "sell" rating to a "hold" rating in a research note on Friday, June 6th. Three analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $9.00.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX traded down $0.07 during mid-day trading on Monday, reaching $3.30. 175,981 shares of the company's stock were exchanged, compared to its average volume of 109,041. Anixa Biosciences has a twelve month low of $2.07 and a twelve month high of $4.20. The business's fifty day moving average price is $3.12 and its 200-day moving average price is $2.98. The firm has a market capitalization of $108.64 million, a price-to-earnings ratio of -9.43 and a beta of 0.58.

Insiders Place Their Bets

In other news, Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm's stock in a transaction that occurred on Thursday, July 31st. The shares were acquired at an average price of $3.08 per share, with a total value of $30,800.00. Following the acquisition, the director owned 953,334 shares of the company's stock, valued at approximately $2,936,268.72. The trade was a 1.06% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders have purchased 35,000 shares of company stock worth $110,700. Corporate insiders own 25.30% of the company's stock.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Benjamin Edwards Inc. purchased a new position in Anixa Biosciences in the 2nd quarter worth approximately $37,000. Jane Street Group LLC grew its stake in Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company's stock worth $138,000 after buying an additional 11,340 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Anixa Biosciences in the 2nd quarter worth approximately $33,000. Marshall Wace LLP purchased a new position in Anixa Biosciences in the 2nd quarter worth approximately $39,000. Finally, Private Advisor Group LLC purchased a new position in Anixa Biosciences in the 1st quarter worth approximately $35,000. Hedge funds and other institutional investors own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.